TFB Advisors LLC Buys 376 Shares of United Therapeutics Co. (NASDAQ:UTHR)

TFB Advisors LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 19.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,291 shares of the biotechnology company’s stock after acquiring an additional 376 shares during the quarter. TFB Advisors LLC’s holdings in United Therapeutics were worth $821,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ClariVest Asset Management LLC boosted its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. USA Financial Formulas bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $33,000. Finally, Values First Advisors Inc. purchased a new stake in shares of United Therapeutics during the third quarter valued at approximately $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $402.57 on Friday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $405.98. The firm has a market capitalization of $17.97 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 1.16 and a beta of 0.56. The stock has a fifty day moving average of $358.27 and a 200 day moving average of $320.94.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.38 EPS. Equities analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $964,983.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $964,983.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,422 shares of company stock worth $29,229,828 in the last quarter. 11.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on UTHR shares. Argus boosted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.